Provided by Tiger Trade Technology Pte. Ltd.

Legend Biotech

18.56
-0.5600-2.93%
Volume:1.67M
Turnover:30.72M
Market Cap:3.61B
PE:-37.06
High:18.91
Open:18.91
Low:18.09
Close:19.12
52wk High:37.50
52wk Low:16.24
Shares:194.49M
Float Shares:193.53M
Volume Ratio:0.92
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5008
EPS(LYR):-1.6200
ROE:-8.08%
ROA:-1.92%
PB:2.94
PE(LYR):-11.46

Loading ...

BUZZ-Genscript hits 4-week high on associate's promising blood cancer cell therapy

Reuters
·
Jun 03

Genscript Biotech Soars on Positive Clinical Data from Affiliate Legend Biotech

Stock News
·
Jun 03

Legend Biotech ADRs Climb on Preliminary Study Results for Non-Hodgkin Lymphoma Treatment

Dow Jones
·
Jun 03

This Is Why Legend Biotech Stock (LEGN) Was Up Today

TIPRANKS
·
Jun 03

Legend Biotech rises 29.5%

TIPRANKS
·
Jun 03

Legend Biotech presents preliminary clinical data for LB2501 at EHA Congress

TIPRANKS
·
Jun 02

Legend Biotech reports 100% response rate in Phase 1 LB2501 in vivo CAR-T trial for relapsed/refractory NHL patients at higher dose cohort

Reuters
·
Jun 02

BRIEF-Legend Biotech Announces Promising Preliminary Clinical Data For LB2501

Reuters
·
Jun 02

Legend Biotech Announces Late-Breaking Oral Presentation at Eha 2026 Showcasing Initial Phase 1 in Vivo CAR-T Data With Lb2501 in Non-Hodgkin Lymphoma (Nhl)

THOMSON REUTERS
·
Jun 02

Legend Biotech: No Dose-Limiting Toxicities, Serious Adverse Events, or Neurotoxicity Reported

THOMSON REUTERS
·
Jun 02

Legend Biotech: 100% Orr (6/6) Observed in Dose Level 2 Cohort, Including Cr Rate of 83.3% (5/6) in Patients With Relapsed/ Refractory Nhl

THOMSON REUTERS
·
Jun 02

Legend's experimental cell therapy shows promise in blood cancer patients

Reuters
·
Jun 02

Legend Biotech: Data Demonstrates Robust in Vivo CAR-T Expansion Without Lymphodepleting Chemotherapy or Bridging Therapy

THOMSON REUTERS
·
Jun 02

Legend Biotech presents first-in-human LB2102 results in solid tumors

TIPRANKS
·
Jun 02

Genscript Highlights Legend Biotech’s New CAR-T Data in Oncology Programs

TIPRANKS
·
Jun 01

Legend Points Carvykti Toward Use in Earlier Setting, RBC Says

MT Newswires Live
·
Jun 01

Legend Biotech Showcases First-in-Human LB2102 Data and Strengthens CARVYKTI Profile at ASCO 2026

TIPRANKS
·
Jun 01

Legend Biotech says Phase 1 LB2102 CAR-T posts 28.6% response rate in relapsed solid tumors at higher doses

Reuters
·
Jun 01

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

GlobeNewswire
·
Jun 01

Oppenheimer Remains a Buy on Legend Biotech (LEGN)

TIPRANKS
·
Jun 01